Another in our series of Themed Podcasts focussing on GU Oncology in China. We are joined by our China Editor, Dr Yao Zhu (Fudan University, Shanghai), and Prof Xuedong Wei (Soochow University, Jiangsu). to find out what the current treatment landscape is for mHSPC in China. Is it ADT/ARPI doublets for all?? Anyone still give chemo? Who gets a PSMA PET/CT? And what is the current status and role for radioligand therapy at progression? Plus, when are we taking GU Cast to Chin again?! All this and more! 

Thanks to our Gold Partner, Bayer China, for supporting our China Themed Episode Series, and for supporting all our GU Cast Conference Highlights. 

Even better on our YouTube channel 

Those two gigantic PSMA review papers in European Urology - Perera et al 2016 and Perera et al 2020 - have been cited more than 2000 times and have been the definitive reference for anyone writing about PSMA PET/CT in the past ten years. And they have just been updated in two new papers just published in European Urology! Previous first author (Marlon) Perera, has moved to senior author, while Elio Mazzone has led both papers as first author, co-ordinating a massive effort between research teams in Melbourne and Milano. One paper is focused on diagnosis and staging, and the other on assessment of recurrence. 
GU Cast co-Hosts Declan Murphy and Renu Eapen are joined from Milano by Elio Mazzoni and Alberto Briganti, and in studio by Marlon Perera, to summarise some of the key findings, and describe the immense effort which went into these papers. Worthy successors to the Perera et al papers of the past! 

Even better on our YouTube channel

Links:
Paper 1: PSMA PET/CT for diagnosis and staging

Paper 2: PSMA PET/CT for recurrence

A beachside interview with Michael Hofman to hear all the PSMA theranostic highlights at ASCO this year! Yes we left our suburban studio in Melbourne and wandered down to St Kilda beach to track down Michael for a beer and a chat. Even in mid-Winter we enjoyed sitting out in a beachside shack at the Beachcomber Cafe and Beach Bar. 
Michael shot some great interviews in Chicago with top clinicians in Nuclear Medicine including Bastiaan Privé, Louise Emmet, Jeremie Calais, Urologist Alberto Briganti, and Medical Oncologist Rana McKay. Great multidisciplinary perspectives on the Bullseye trial, Violet, Enza-P plus much more.  Including a chat about the great promise of CAIX in renal cancer. 



With your usual hosts, Renu Eapen and Declan Murphy

Enjoy the beachside chat even more on our YouTube channel

GU Cast Conference Highlights are supported by our Gold Partners, Bayer China.

Links:
Beachside Bar, St Kilda 

What is Histolog?? Well, now that intra operative margin assessment is a such a hot topic in prostate cancer surgery after the Neurosafe RCT read-out, we thought we would dive into one of the other new technologies for doing something similar, but without the pragmatic challenges of frozen section.  The idea is to assess the surgical margin of the prostate at the time of surgery to improve nerve sparing and sexual function for patients.

We are joined by Professor Greg Shaw (University College London, UK), PI of the Neurosafe Proof trial, which we already featured following their Lancet Oncology paper in March 2025,  and our colleague Professor Nathan Lawrentschuk (Peter MacCallum Cancer Centre, AUS), who is leading a study of the Histolog device here in Melbourne. We chat first about Neurosafe and why intra-operative margin assessment is important, and then dive into Histolog which Greg has some experience with. 

Histolog uses confocal laser microscopy to assess the prostate specimen at the time of surgery, with a similar principle to frozen section analysis as used in the Neurosafe technique. However Histolog offers a lot more convenience and removes some of the practical barriers we face with frozen section, which are barriers to implementation. But is it as good as frozen section? Join your usual hosts Declan Murphy and Renu Eapen to find out more. 

Many thanks to our Silver Partners, Device Technologies, who are distributing the Histolog technology here in Australia, and to Samantree who are the manufacturers of the Histolog device. 

This episode better enjoyed on our YouTube channel (if you don't mind some surgical scenes)!

Links
Previous GU Cast on Neurosafe with Greg Shaw and colleagues
Histolog device manufacturer website 

A wonderful meandering chat with Ketan Badani (Urologist, Mt Sinai, NYC)! We took him for a wine tour in the Yarra Valley, stopping for a pod chat at Rochford Winery about screening for prostate cancer in older men, plus a great tour around Healesviile Sanctuary to introduce Ketan to some Australian wildlife. Then back in Melbourne we had another chat, this time a bit of future-gazing about the future of surgery, and Declan and Ketan trade tales about EMR (that's Electronic Medical Record) delinquency. 

Ketan was visiting Melbourne as a guest of Device Technologies to speak at the Epworth Healthcare Robotic Urology Masterclass. And what a great guest he was! 

With your usual hosts Renu Eapen and Declan Murphy. Thanks to our fantastic guide Trish at Healesville Sanctuary, and Beatrice who looked after us at Rochford Winery.

This one much better enjoyed on our YouTube channel!

Links:
Rochford Winery
Healesville Sanctuary 

A Masterclass in advanced kidney cancer today with the great Danny Heng (University of Calgary, Canada), and our own Lewis Au (Peter MacCallum Cancer Centre, Melbourne). Both popped into the GU Cast studio while Danny was in Australia doing some lectures and visiitng us at Peter Mac.
We challenged Danny and Lewis to simplify three hot topics in kidney cancer, ideal if (like us) you find it difficult to keep up with this fast-moving area. The three areas are:
1. What sort of patient is this? Risk stratification made easy (by Danny, Master of the universe of Risk Stratification in kidney cancer)
2. Novel scans and biomarkers in kidney cancer - a bluffers guide
3. Neoadjuvant and adjuvant therapies in kidney cancer - what the urologist needs to know

Even better on our YouTube channel

Meet the young new faces of collaborative urological research!!  GU Cast host Declan Murphy discusses the latest in international collaborative trials with A/Prof Veeru Kasivisvanathan, Dr Alexander Ng, and highly ambitious medical students, Miss Aishwarya Shah and Mr Alexander Dudko. They discuss their latest research from the COMPASS group including the PRIME trial (bpMRI vs mpMRI in detecting prostate cancer), and upcoming PARADIGM (AI vs Radiologists in detecting prostate cancer trials. And from BURST Urology we hear an update from the RESECT (can audit and feedback improve TURBT outcomes?) trial. The team discusses mentorship and bringing up the next generation of early career researchers, including medical students and early-stage trainees.

Even better on our Youtube channel

Links:
·         COMPASS
·         PRIME DOI
·         PARADIGM DOI
·         BURST
·         RESECT DOI

When Fred Saad (Urologist, University of Montreal, Montreal) and Andrew Weickhardt (Medical Oncologist, Austin Health, Melbourne) popped into our studio recently we decided to pick their brains on a few hot topics in mHSPC - we called it the ABC of mHSPC! Fred was in Melbourne to visit Peter Mac and do some educational talks and we loved welcoming him back on GU Cast. 

A is for ARPIs - who/when/which? 
B is for treatment Break - can we use an intermittent approach to ADT/ARPI doublets without yet having trials in the ARPI era to guide us? 
C is for Chemo - surely there is almost no role for docetaxel chemo in the ARPI era?? Or so asks Declan, well known triplet therapy sceptic! Do Fred and Andrew agree??!

A great overview of hot topics in mHSCP! Thanks to Fred and Andrew! With your usual hosts Declan Murphy and Renu Eapen.

Even better on our YouTube channel 

A big welcome back to EAU Guideline gurus, Dr Derya Tilki (Martini-Klinik, Hamburg, Germany), and Dr Gianluca Giannarini (Santa Maria della Misericordia University Hospital, Udine, Italy), for an overview of the major headlines from this year's EAU Guideline update. Derya is Deputy Chair of the EAU Prostate Cancer Guideline Committee and has picked out four areas to discuss. These are:
1. New stratification for favourable and unfavourable prostate cancer
2. PSMA PET/CT now recommended for unfavourable intermediate-risk cancer
3. No change to PLND recommendations due to lack of benefit in MSKCC RCT update
4. Importance of multidisciplinary approach for mHSPC

So tune in so you can pretend you have read the full 250 page 2025 Guideline!!

Your usual co-hosts are Professor Declan Murphy and Dr Renu Eapen.

Even better on our Youtube channel

Links:
Updated 2025 EAU Prostate Cancer Guideline 

For serious PSMA theranostics enthusiasts!!! We bring you the ninth of our collaborative PSMA webinars over the past five years, in collaboration with our team at ProsTIC and at the Prostate Cancer Foundation in the US. A truly outstanding faculty presenting today including Misha Beltran, Marty Pomper, Ed Kwan and Louise Emmett.

Co-hosted by Declan Murphy and Michael Hofman with a welcome from Howard Soule and Andrea Miyahira. Declan and Michael are joined in studio by Louise Kostos who helps field the many questions from the huge global audience who joined us live. 

Much better appreciated on our YouTube channel where you can see all the presentations